These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 3719900)
1. Renal function in the elimination of oral melphalan in patients with multiple myeloma. Adair CG; Bridges JM; Desai ZR Cancer Chemother Pharmacol; 1986; 17(2):185-8. PubMed ID: 3719900 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of oral melphalan in relation to renal function in multiple myeloma patients. Osterborg A; Ehrsson H; Eksborg S; Wallin I; Mellstedt H Eur J Cancer Clin Oncol; 1989 May; 25(5):899-903. PubMed ID: 2737222 [TBL] [Abstract][Full Text] [Related]
3. Plasma melphalan and prednisolone concentrations during oral therapy for multiple myeloma. Taha IA; Ahmad RA; Gray H; Roberts CI; Rogers HJ Cancer Chemother Pharmacol; 1982; 9(1):57-60. PubMed ID: 7139852 [TBL] [Abstract][Full Text] [Related]
4. The pharmacokinetics of melphalan during intermittent therapy of multiple myeloma. Loos U; Musch E; Engel M; Hartlapp JH; Hügl E; Dengler HJ Eur J Clin Pharmacol; 1988; 35(2):187-93. PubMed ID: 3191937 [TBL] [Abstract][Full Text] [Related]
6. Comparison of the fed and fasting states on the absorption of melphalan in multiple myeloma. Bosanquet AG; Gilby ED Cancer Chemother Pharmacol; 1984; 12(3):183-6. PubMed ID: 6705135 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of high-dose melphalan in adults: influence of renal function. Kergueris MF; Milpied N; Moreau P; Harousseau JL; Larousse C Anticancer Res; 1994; 14(6A):2379-82. PubMed ID: 7825976 [TBL] [Abstract][Full Text] [Related]
8. Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study. Tricot G; Alberts DS; Johnson C; Roe DJ; Dorr RT; Bracy D; Vesole DH; Jagannath S; Meyers R; Barlogie B Clin Cancer Res; 1996 Jun; 2(6):947-52. PubMed ID: 9816255 [TBL] [Abstract][Full Text] [Related]
9. Toxicity in standard melphalan-prednisone therapy among myeloma patients with renal failure--a retrospective analysis and recommendations for dose adjustment. Carlson K; Hjorth M; Knudsen LM; Br J Haematol; 2005 Mar; 128(5):631-5. PubMed ID: 15725084 [TBL] [Abstract][Full Text] [Related]
10. The pharmacokinetics of melphalan in patients with multiple myeloma: an intravenous/oral study using a conventional dose regimen. Woodhouse KW; Hamilton P; Lennard A; Rawlins MD Eur J Clin Pharmacol; 1983; 24(2):283-5. PubMed ID: 6840181 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of oral and intravenous melphalan during routine treatment of multiple myeloma. Bosanquet AG; Gilby ED Eur J Cancer Clin Oncol; 1982 Apr; 18(4):355-62. PubMed ID: 6889512 [TBL] [Abstract][Full Text] [Related]
12. Glomerular filtration rate prior to high-dose melphalan 200 mg/m(2) as a surrogate marker of outcome in patients with myeloma. Sirohi B; Powles R; Kulkarni S; Rudin C; Saso R; Rigg A; Horton C; Singhal S; Mehta J; Treleaven J Br J Cancer; 2001 Aug; 85(3):325-32. PubMed ID: 11487259 [TBL] [Abstract][Full Text] [Related]
13. Cyclophosphamide-containing regimen (TCD) is superior to melphalan-containing regimen (MPT) in elderly multiple myeloma patients with renal impairment. Song MK; Chung JS; Shin HJ; Moon JH; Lee JJ; Yoon SS; Kim JS; Lee JO; Do YR; Lee HS; Park EK; Ann Hematol; 2012 Jun; 91(6):889-96. PubMed ID: 22237937 [TBL] [Abstract][Full Text] [Related]
14. Effect of renal dysfunction in dogs on the disposition and marrow toxicity of melphalan. Alberts DS; Chen HG; Benz D; Mason NL Br J Cancer; 1981 Mar; 43(3):330-4. PubMed ID: 7225283 [TBL] [Abstract][Full Text] [Related]
15. Intermediate-dose (25mg/m2) IV melphalan for multiple myeloma with renal failure. Vigneau C; Ardiet C; Bret M; Laville M; Fiere D; Tranchand B; Fouque D J Nephrol; 2002; 15(6):684-9. PubMed ID: 12495285 [TBL] [Abstract][Full Text] [Related]
16. Melphalan 200 mg/m2 with blood stem cell support as first-line myeloma therapy: impact of glomerular filtration rate on engraftment, transplantation-related toxicity and survival. Carlson K Bone Marrow Transplant; 2005 May; 35(10):985-90. PubMed ID: 15806125 [TBL] [Abstract][Full Text] [Related]